<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1447028/000117184323001710/f8k_031523.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1447028/000117184323001710/0001171843-23-001710-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 8.01 Item 9.01

Arbutus Biopharma Corp

Analyst Summary: Arbutus Biopharma Corporation has announced the dosing of the first subject in a Phase 1 clinical trial of its oral RNA destabilizer, AB-161, for the treatment of chronic hepatitis B virus (HBV) infection. The trial will investigate the safety, tolerability, and pharmacokinetics of AB-161 in healthy subjects, with initial data expected in the second half of 2023. Arbutus is committed to advancing its pipeline in developing an all-oral treatment regimen for patients with chronic HBV. Chronic HBV infection represents a significant unmet medical need, affecting over 290 million people worldwide, with approximately 820,000 resulting in death every year from complications. Management said, "We remain committed to advancing our pipeline of assets to develop a functional cure for chronic HBV and look forward to sharing the initial data from the Phase 1 clinical trial of AB-161." However, cautionary statements related to business, economic, competitive, market, and social uncertainties could materially impact future results, achievements, and expectations of success.

$ABUS reports AB-161 Phase 1 clinical trial initiation for chronic HBV treatment

Announcement: ABUS 8-K Special Filing

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1447028/000117184323001679/f8k_031423.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1447028/000117184323001679/0001171843-23-001679-index.htm>Original filing index</a>
                    </div>

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1447028/000144702823000018/abus-20221231.htm>Download 10-K Annual Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1447028/000144702823000018/0001447028-23-000018-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Arbutus Biopharma announces AB-729 progress ##:
Phase 2 clinical trials on Arbutus Biopharma's AB-729 shows encouraging results with no adverse effects. Arbutus Biopharma's RNAi therapeutic holds potential for treating chronic hepatitis B virus infections by re-awakening the immune system. Arbutus Biopharma is anticipating long-term suppression of HBS in more trials to come. However, Arbutus Biopharma advised caution, knowing that COVID-19 could cause significant disruptions, leading to delays or shortages in any clinical development. Arbutus Biopharma intends to continue the complete development of RNA interference, inhibitors to fight viral diseases.

Announcement: ABUS 10-K Annual Report

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1447028/000117184323001339/f8k_030223.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1447028/000117184323001339/0001171843-23-001339-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 2.02 Item 8.01 Item 9.01

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/1447028/000117184323000518/f8k_012623.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/1447028/000117184323000518/0001171843-23-000518-index.htm>Original filing index</a>
                        </div>

Form 8-K - Current report - Item 5.02 Item 9.01

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/1447028/000117184323000071/f8k_010523.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/1447028/000117184323000071/0001171843-23-000071-index.htm>Original filing index</a>
                        </div>